BACKGROUND: WHO grade 3 gliomas include anaplastic oligodendroglioma (AO), anaplastic astrocytoma (AA), and anaplastic oligoastrocytoma (AOA). There is limited data on prognostic factors for this population. METHODS: WHO grade 3 gliomas diagnosed 2007-2014 were identified through the Cleveland Clinic's IRB approved database. Proportional hazards models with stepwise variable selection were used to identify prognostic factors for overall survival (OS) from diagnosis. RESULTS: Data from 199 patients were analyzed. 57% were male; median age at diagnosis was 49 years (range, 19-86); 72% had Karnofsky performance status (KPS) ≥80. Co-deletion of 1p/19q occurred in 19% (32/159), median Ki-67 expression was 20% (range 1-80) in 168 patients, 28% (45/160) had abnormal EGFR expression; p53 expression was 0-10% in 48% (76/159). 46% of patients had total/near total resections, 20% subtotal resections; 33% biopsy only. 66% of patients received upfront chemoradiation, 17% chemotherapy (10%) or radiation (7%) only; 16% supportive care. Median OS was 63.2 months; 2-year survival 68% ± 4%. Age (<50 vs ≥50, p < .0001), histology (AO or AOA vs AA or unspecified, p = .002), KPS (≥80 vs <80, p = .01) and multifocal disease (absent vs present, p = .02) were identified as independent predictors. These were combined to form 3 clinical groups (CG; CG 1 had the best prognosis; CG 3 the worst). Adjusting for CG Ki-67 (≤10% vs >10%) provided additional prognostic information, which when added to CG resulted in 4 distinct prognostic groups: a very small favorable group (CG 1 and Ki-67 ≤10%, n = 9%, no deaths reported, 24.4 month median follow-up), favorable (CG 1/Ki-67 > 10%, n = 49%, 86% ± 5% 2-year survival), intermediate (CG 2/Ki-67 > 10% or CG 3/Ki-67 ≤ 10%, n = 23%, 54% ± 11% 2-year survival), and unfavorable (CG 3 and Ki-67 > 10%, n = 19%, 0% 2-year survival). CONCLUSION: Older age, poor KPS, AA and unspecified histology, multifocal disease, and positive Ki-67 expression are associated with higher mortality in this population.
. 2015 Nov 9;17(Suppl 5):v80. doi: 10.1093/neuonc/nov213.11
EPID-11: WHO GRADE 3 GLIOMAS: CLINICAL AND MOLECULAR PROGNOSTIC FACTORS
Ming Chi
1, Nehaw Sarmey
3, Lauren Gotterer
2, Zhijian Chen
2, Glen Stevens
2, David Peereboom
1,2, Paul Elson
4, Manmeet Ahluwalia
1,2
Nehaw Sarmey
3Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA
Find articles by Nehaw Sarmey
Lauren Gotterer
2Neurological Institute, Cleveland Clinic, Cleveland,OH, USA
Find articles by Lauren Gotterer
Zhijian Chen
2Neurological Institute, Cleveland Clinic, Cleveland,OH, USA
Find articles by Zhijian Chen
Glen Stevens
2Neurological Institute, Cleveland Clinic, Cleveland,OH, USA
Find articles by Glen Stevens
David Peereboom
1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
2Neurological Institute, Cleveland Clinic, Cleveland,OH, USA
Find articles by David Peereboom
Paul Elson
4Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA
Find articles by Paul Elson
Manmeet Ahluwalia
1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
2Neurological Institute, Cleveland Clinic, Cleveland,OH, USA
Find articles by Manmeet Ahluwalia
1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
2Neurological Institute, Cleveland Clinic, Cleveland,OH, USA
3Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA
4Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA
Issue date 2015 Nov.
Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.
PMCID: PMC4638751
